Larry Steven Mcdaniel

US Patent:

59978821, Dec 7, 1999

Filed:

Jun 6, 1995

Appl. No.:

8/468985

Inventors:

David E. Briles - Birmingham AL
Janet L. Yother - Birmingham AL
Larry S. McDaniel - Birmingham AL

Assignee:

UAB Research Foundation - Birmingham AL

International Classification:

A61K 3909

US Classification:

4242441

Abstract:

Regions of the PspA protein of the R. times. 1 strain of Streptococcus pneumoniae have been identified as containing protection-eliciting epitopes which are cross-reactive with PspAs of other S. pneumoniae strains and which is cross-protective. One region comprises the 68-amino acid sequence extending from amino acid residues 192 to 260 of the R. times. 1 PspA strain while another region comprises the C-terminal amino acid sequence extending from amino acid residues 293 to 588 of the R. times. 1 PspA strain.

US Patent:

59651415, Oct 12, 1999

Filed:

May 20, 1994

Appl. No.:

8/246636

Inventors:

David E. Briles - Birmingham AL
Janet L. Yother - Birmingham AL
Larry S. McDaniel - Birmingham AL

Assignee:

UAB Research Foundation - Birmingham AL

International Classification:

A61K 3909

US Classification:

4242441

Abstract:

A region of the PspA protein of the Rx1 strain of Streptococcus pneumoniae has been identified as containing protection-eliciting epitopes which are cross-reactive with PspAs of other S. pneumoniae strains and which is cross-protective. The region comprises the 68-amino acid sequence extending from amino acid residues 192 to 260 of the Rx1 PspA strain.

US Patent:

62318705, May 15, 2001

Filed:

Jun 2, 1995

Appl. No.:

8/458399

Inventors:

David E. Briles - Birmingham AL
Larry S. McDaniel - Ridgeland MS
Masafumi Yamamoto - Birmingham AL
Hiroshi Kiyono - Birmingham AL

Assignee:

UAB Research Foundation - Birmingham AL

International Classification:

A61K 3909
C12N 1500
C12N 120

US Classification:

4242441

Abstract:

Oral or peroral administration, including intragastrically, of killed whole pneumococci, lysate of pneumococci and isolated and purified PspA, as well as immunogenic fragments thereof, particularly when administered with an adjuvant such as cholera toxin provides protection in a host, animal or human, against pneumococcal infection, including colonization, and systemic infection, such as sepsis. The ability to elicit protection against pneumococcal colonization in a host prevents carriage among immunized individuals, which can lead to elimination of disease from the population as a whole.

US Patent:

54769299, Dec 19, 1995

Filed:

Jun 3, 1993

Appl. No.:

8/072070

Inventors:

David E. Briles - Birmingham AL
Janet L. Yother - Birmingham AL
Larry S. McDaniel - Birmingham AL

Assignee:

UAB Research Foundation - Birmingham AL

International Classification:

C07H 2104

US Classification:

536 2432

Abstract:

A purified pneumococcal surface protein A (PspA) comprises a truncated form of the PspA protein which is immunoprotective and contains the protective epitopes of PspA. The PspA protein is soluble in physiologic solution and lacks at least the cell membrane anchor region of the whole protein. The protein is formed by insertion-duplication of mutagenesis of S. pneumoniae with pspA gene and expression of the truncated protein into the growth medium.

US Patent:

60048026, Dec 21, 1999

Filed:

May 30, 1996

Appl. No.:

8/657751

Inventors:

David E. Briles - Birmingham AL
Larry S. McDaniel - Ridgeland MS
Masafumi Yamamoto - Birmingham AL
Hiroshi Kiyono - Birmingham AL

Assignee:

University of Alabama at Birmingham - Birmingham AL

International Classification:

C12N 1500
A61K 3909

US Classification:

4353201

Abstract:

Oral or peroral administration, including intragastrically, of killed whole pneumococci, lysate of pneumococci and isolated and purified PspA, as well as immunogenic fragments thereof, particularly when administered with an adjuvant such as cholera toxin provides protection in a host, animal or human, against pneumococcal infection, including colonization, and systemic infection, such as sepsis. The ability to elicit protection against pneumococcal colonization in a host prevents carriage among immunized individuals, which can lead to elimination of disease from the population as a whole.

US Patent:

62321161, May 15, 2001

Filed:

Jun 7, 1995

Appl. No.:

8/482981

Inventors:

David E. Briles - Birmingham AL
Larry S. McDaniel - Ridgeland MS
Masafumi Yamamoto - Birmingham AL
Hiroshi Kiyono - Birmingham AL

Assignee:

University of Alabama at Birmingham Research Foundation - Birmingham AL

International Classification:

A61K 3909
C12N 1500

US Classification:

4353201

Abstract:

Oral or peroral administration, including intragastrically, of killed whole pneumococci, lysate of pneumococci and isolated and purified PspA, as well as immunogenic fragments thereof, particularly when administered with an adjuvant such as cholera toxin provides protection in a host, animal or human, against pneumococcal infection, including colonization, and systemic infection, such as sepsis. The ability to elicit protection against pneumococcal colonization in a host prevents carriage among immunized individuals, which can lead to elimination of disease from the population as a whole.

US Patent:

59809094, Nov 9, 1999

Filed:

Oct 7, 1994

Appl. No.:

8/319795

Inventors:

David E. Briles - Birmingham AL
Janet L. Yother - Birmingham AL
Larry S. McDaniel - Birmingham AL

Assignee:

UAB Research Foundation - Birmingham AL

International Classification:

A61K 3909

US Classification:

4242441

Abstract:

Regions of the PspA protein of the Rx1 strain of Streptococcus pneumoniae have been identified as containing protection-eliciting epitopes which are cross-reactive with PspAs of other S. pneumoniae strains and which is cross-protective. One region comprises the 68-amino acid sequence extending from amino acid residues 192 to 260 of the Rx1 PspA, another region comprises the C-terminal amino acid sequence extending from amino acid residues 293 to 588 of the Rx1 PspA, while a third region comprises the N-terminal amino acid sequence extending from amino acid residues 1 to 115 of the Rx1 PspA.